Johnson & Johnson is set to report first-quarter 2026 earnings on Monday that exceed Wall Street consensus estimates, with the company's MedTech division and oncology drug portfolio continuing to outperform amid a challenging macroeconomic environment. Analysts surveyed by Bloomberg had projected earnings per share of approximately $2.58 on revenues near $22.7 billion, but early indications from supply chain data and hospital utilisation trends suggest J&J will clear both benchmarks comfortably.

The MedTech segment, which encompasses surgical robotics, orthopaedics, and cardiovascular devices, has benefited from a post-pandemic recovery in elective procedure volumes that has proven more durable than many analysts anticipated. The division's Shockwave Medical acquisition, completed in late 2024, is expected to show meaningful revenue contribution for the second consecutive quarter, adding momentum to J&J's cardiovascular ambitions.

On the pharmaceutical side, cancer therapies including Darzalex and Tecvayli are anticipated to post double-digit year-over-year growth, partially offsetting continued erosion from biosimilar competition against legacy drugs. Chief Executive Officer Joaquin Duato is expected to highlight the company's pipeline depth during the post-earnings conference call, pointing to late-stage trials in autoimmune and neurological indications as growth drivers through 2027 and beyond.

The earnings report arrives against a backdrop of broader tariff uncertainty weighing on US manufacturing inputs. J&J, which sources components across Asia and Europe, has flagged modest cost headwinds from trade policy changes, but analysts expect management to characterise the exposure as manageable given the company's diversified geographic manufacturing footprint and long-term supplier contracts.

Should J&J raise its full-year adjusted earnings guidance — currently centred around $10.55 per share — the move would likely provide a positive signal for the broader healthcare sector during an earnings season marked by caution. Investors will closely watch commentary on the company's litigation reserve related to talc-based baby powder claims, where a proposed settlement framework remains under judicial review in federal bankruptcy court.